



Lobular Breast Cancer
Research Program
Department of Surgery



SYMPOSIUM
2026

2026 International Invasive Lobular Carcinoma Symposium

SEPTEMBER 23 - 25, 2026 | SAN FRANCISCO, CA

www.ilcsymposium.com



Table of Contents

Welcome.....	3
History of Symposium.....	4
Symposium Highlights.....	5
Agenda.....	6
Sponsors.....	11
Keynote Speakers.....	12
Session Speakers.....	13
Conference Abstracts.....	20
Awards for Abstract Submissions.....	23
Welcome to San Francisco.....	24
Planning Committees.....	25
2028 ILC Symposium Location.....	28
Sponsor Highlights.....	29
In Memoriam.....	32
Notes.....	34



Welcome

Welcome from the Chair of the UCSF Department of Surgery

Dear conference attendees,

As Chair of the Department of Surgery at the University of California, San Francisco, it is my pleasure to welcome you to San Francisco for the 2026 International Invasive Lobular Carcinoma Symposium. We are proud to serve as host and sponsor for this vital gathering of international leaders, clinicians, scientists, patient advocates, and trainees.


Invasive lobular carcinoma (ILC) represents a clinically and biologically distinct disease that demands dedicated focus, rigorous scientific inquiry, and collaborative innovation. Our department is deeply committed to supporting groundbreaking translational research and fostering cross-disciplinary collaboration. Seeing this international group convene, actively bridging the gap between bench science, clinical care, and patient advocacy, embodies the very best of academic medicine and community engagement.

We extend our sincere gratitude to the symposium leadership, and especially Dr. Rita Mukhtar, Professor of Surgery and Program Director of the UCSF Lobular Breast Cancer Research Program, the scientific and advocate planning committees, and our co-sponsors whose vision and tireless work brought this event to fruition. Most importantly, we thank each of you for traveling from near and far to lend your expertise and passion.

Over the course of this meeting, I hope you find yourselves energized by new data, engaged in vigorous discussion, and inspired by the powerful partnerships taking shape across disciplines and borders. The work done in these rooms directly shapes the future of ILC care and brings meaningful hope to the patients and families we serve.

Welcome to UCSF and to San Francisco; have a wonderful meeting!

Warm regards,



Julie Ann Sosa, MD, MA, FACS, FSSO

Leon Goldman, MD Distinguished Professor of Surgery and Chair, Department of Surgery
Professor, Department of Medicine

Affiliated faculty, Philip R. Lee Institute for Health Policy Studies University of California San Francisco (UCSF)

History of ILC Symposium

Founded in 2016 in Pittsburgh, Pennsylvania, the International Invasive Lobular Carcinoma (ILC) Symposium was established as the first scientific meeting dedicated entirely to invasive lobular carcinoma. The original symposium logo, designed by Daniel Brown, reflected a defining feature of ILC: its single-file growth pattern, represented through the use of yellow circles.



The symposium's growth is reflected in the evolution of its logo. The new logo, designed by Kristine Sikora, preserves a connection to ILC biology through the single-file dotted lines, while also symbolizing progress and collaboration. The upward arc represents the symposium's continued expansion, while the four dotted lines reflect the clinicians, researchers, scientists, and patient advocates who come together to advance the field of lobular breast cancer.



Since 2016, the ILC Symposium has been held every 1-2 years in rotating locations, and continues to grow in its international impact.

We are deeply grateful to **Daniel Brown** and **Kristine Sikora**, whose thoughtful designs for the symposium's logos, website, and imagery beautifully capture the spirit of the ILC Symposium.

Symposium Highlights


2026 ILC Symposium BY THE NUMBERS




300+
ATTENDEES



5
CONTINENTS




11
COUNTRIES



28
U.S. STATES



121
ACADEMIC
INSTITUTIONS AND
ORGANIZATIONS



Agenda

WEDNESDAY, SEPTEMBER 23, 2026

7:30 am - 11:45 am **Patient Advocate Session** | Garden Room
Breakfast Included

10:30 am - 12:45 pm **Symposium Registration Opens** | Bayview Foyer A

11:45 am - 12:45 pm **Welcome Lunch** | Bayview Foyer A
Open to all conference attendees

12:45 pm - 1:00 pm **Opening of the Symposium** | Bayview Room
Rita Mukhtar, MD, 2026 ILC Symposium Host

1:00 pm - 1:30 pm **Debate 1: Tumor morphology alone should be used to diagnose ILC** | Bayview Room

SPEAKERS: Fouad Boulous, MD and Stu Schnitt, MD | **DISCUSSANT:** Anne Vincent-Salomon, MD, PhD

1:30 pm - 2:45 pm **Scientific Session 1: Genetics, Risk, and Exposures** | Bayview Room
Moderators: Fresia Pareja, MD, PhD & Nicole Dearing

- Pathogenic germline variants in invasive lobular breast cancer — **Giovanni Corso, MD, PhD**
- Hormonal exposures in ILC development — **Cathrin Briskin, MD, PhD**
- Latest data in hormone replacement therapy — **Mindy Goldman, MD**
- Lobular carcinoma in situ: management strategies — **Tari King, MD**

2:45 pm - 3:00 pm **Snacks and Exhibits Break** | Bayview Foyer A

3:00 pm - 4:00 pm **Oral Abstract Presentations Session #1** | Bayview Room
Podium Presentations (6 minutes each)

- AP-2 β Defines a Mammary Epithelial Subpopulation With a Potential Role in Lobular Carcinoma Initiation — **Christopher Merkel, BS**
- Incidence of bilateral breast cancer in patients with invasive lobular carcinoma of the breast: an institutional cohort study of 998 patients — **Anna Vertido, MD**
- Modeling recurrent ILC as a platform for the development of novel therapeutics — **Sumayya Abdul Qadir, BS**
- Context-dependent tumor suppressor role of RHOA in breast cancer through cooperation with CDH1 loss — **Higinio Dopeso, PhD**

Agenda

3:00 pm - 4:00 pm

Oral Abstract Presentations Session #1 | Bayview Room

Podium Quickshot Presentations (3 minutes each)

- Beyond E-cadherin: Histologic and immunohistochemical features of invasive lobular carcinomas with non-truncating CDH1 mutations — **Julia Ye, MD, PhD**
- Relative rates of ILC incidence in Colorado reflect socioeconomic or structural factors that may drive disparities in ILC diagnoses — **Melanie Q. Salvador, BS**
- Phenotypic characterization of tumor cells across non-blood body fluids from patients with metastatic invasive lobular breast cancer (ILC) and invasive breast cancer of no special type (IBC-NST) — **Camille Carette, MS**
- PDOmics: Patient-Derived Organoids as a Multi-Omic Window into ILC Heterogeneity and Clinical Behavior — **Brent Schlegel, BS**
- LobSig, a prognostic biomarker set for ILC: where are we and why has it taken so long? — **Amy McCart Reed, PhD**

4:00 pm - 5:15 pm

Scientific Session 2: The ILC Cell & Microenvironment | Bayview Room

Moderators: Rachel Natrajan, PhD & Carolyn Reuss

- Unique proteomic features of ILC — **Chip Petricoin, PhD**
- Tumor microenvironment in ILC — **Fatima Mechta-Grigoriou, PhD**
- Metabolism in ILC — **Rebecca Riggins, PhD**
- New methods to study cell cycle in ILC — **Wayne Stallaert, PhD**

5:15 pm - 6:00 pm

Advocate Research RoundUp | Bayview Room

Moderators: Rebecca Shatsky, MD & Matthew Sikora, PhD

5:30 pm - 7:30 pm

Poster Session and Networking | Garden Room

THURSDAY, SEPTEMBER 24, 2026

7:00 am - 8:00 am

Breakfast Banter and Breakthroughs | Garden Room

Registration Required | Advocate and Researcher Tables

8:00 am - 9:15 am

Scientific Session 3: Mechanisms of Metastasis | Bayview Room

Moderators: Julia Houthuijzen, PhD & Andrea Lener

- Metastatic interactome: collective cell migration in breast cancer — **Kevin Cheung, MD**
- Autophagy in breast cancer — **Jay Debnath, MD**
- Novel treatment targets in metastatic ILC — **Chris Lord, PhD**
- Tissue mechanics in ER positive breast cancer — **Valerie Weaver, PhD**

Agenda

9:15 am - 9:45 am **Debate 2: Cytotoxic chemotherapy is ineffective in patients with metastatic ILC** | Bayview Room

SPEAKERS: Rebecca Shatsky, MD and Sherry Shen, MD

9:45 am - 10:15 am **Group Photo & Exhibits Break** | Hotel Lobby & Bayview Foyer A

10:15 am - 11:30 am **Scientific Session 4: Model Systems & Pathology** | Bayview Room
Moderators: Anne Vincent-Salomon, MD, PhD & Ciara Gustafson

- The expanding repertoire of preclinical models of ILC — **Adrian Lee, PhD**
- Somatic genome editing in rats enables ILC modeling — **Yi Li, PhD**
- A New Era for ILC Histologic Variants: From Improved Morphological Criteria to AI-Based Prediction — **Lounes Djerroudi, MD, PhD**
- Mitotic vulnerabilities of ILC — **Ruth Keri, PhD**

11:30 am - 12:00 pm **Keynote Address 1: Hereditary CDH1 Mutations: The identification and evolution of a cancer syndrome** | Bayview Room

KEYNOTE SPEAKER: Parry Guilford, PhD

12:00 pm - 1:15 pm **Lunch** | Garden Room

1:15 pm - 2:30 pm **Scientific Session 5: Diagnostics & Clinical Management** | Bayview Room
Moderators: Suzanne Conzen, MD & Jade Moran

- Unique aspects of ILC in pre-menopausal patients — **Rachel Jankowitz, MD**
- Modifiable risk factors impacting ILC outcomes — **Karen van Baelen, MD, PhD**
- Management of the axilla in ILC — **Priscilla McAuliffe, MD, PhD**
- Immunotherapy in ILC: tumor microenvironment for treatment selection — **Jason Mouabbi, MD**

2:30 pm - 3:30 pm **Oral Abstract Presentations Session #2** | Bayview Room
Podium Presentations (6 minutes each)

- Multimodal analysis of tumour evolution in ILC reveals dynamic changes in extracellular matrix — **Renee Flaherty, PhD**
- The accuracy of whole-body diffusion-weighted MRI in the staging of invasive lobular breast carcinoma: a retrospective study — **Richard Heeren, MD**
- The tumour microenvironment as source for prognostic biomarkers in invasive lobular breast cancer — **Eduardo Pena, PhD**
- IvoLoC: A Phase II Trial of Ivonescimab (IVO) in Endocrine-Refractory Hormone Receptor (HR)-Positive or Triple-Negative (TN) metastatic Invasive Lobular Carcinoma (mILC) — **Jason Mouabbi, MD**

Agenda

2:30 pm - 3:30 pm

Oral Abstract Presentations Session #2 | Bayview Room

Podium Quickshot Presentations (3 minutes each)

- Leveraging Focal Adhesion Dependencies in CDH1-deficient Lobular Breast Cancer — **Darcie Seachrist, PhD**
- Clinical utility and management impact of 18F-FES PET/CT for Estrogen Receptor Positive Breast Cancer — **Chamil Jinadasa, MD**
- Omission of axillary surgery in patients with invasive lobular carcinoma of the breast: rates of nodal involvement in clinically node negative patients and impact on recurrence in a single institution analysis — **Elisabeth Abeles, MD**
- Utilization of a Supine MRI-based Guidance System, The Breast Cancer Locator™, to Decrease Positive Margin Rates after Lumpectomy: an International Randomized Prospective Trial — **Richard Barth, MD**
- Spatial ecotypes within hormone-positive invasive lobular carcinoma uncover distinct immune microenvironment from invasive ductal carcinoma — **Marni McClure, MD, PhD**
- Introducing an ILC Dependency Atlas — **Rachel Brough, PhD**

3:30 pm - 3:45 pm

Snacks and Exhibits Break | Bayview Foyer A

3:45 pm - 5:00 pm

Scientific Session 6: Clinical Trial Results & Advocacy

Moderators: Megan Kruse, MD & Deborah Romer

- PELOPS — **Rinath Jeselsohn, MD, PhD**
- Neoadjuvant neratinib — **Laura Kennedy, MD**
- LOBSTER — **Maria Karsten, MD**
- Integrating patient advocates in ILC research — **Mo Rimawi, MD**

5:00 pm - 5:45 pm

Advocate Research RoundUp | Bayview Room

Moderators: Giovanni Corso, MD, PhD & Amy McCart Reed, PhD

6:30 pm - 8:00 pm

Symposium Banquet | Garden Room

Registration Required

FRIDAY, SEPTEMBER 25, 2026

7:00 am - 8:00 am

Breakfast | Garden Room

8:00 am - 9:00 am

Scientific Session 7: Endocrine Resistance & Novel Targets | Bayview Room

Moderators: Pete Simpson, PhD & Megan-Claire Chase

- Endocrine therapy resistance in ILC — **Ariella Hanker, PhD**
- Liquid biopsy other than blood — **François Richard, PhD**
- Combined vulnerabilities and potential interventions — **Patrick Derksen, PhD**

Agenda

9:00 am - 9:30 am	Keynote Address 2: Novel approaches to screening and clinical trials for breast cancer: how to improve care for ILC Bayview Room KEYNOTE SPEAKER: Laura Esserman, MD, MBA
9:30 am - 10:00 am	Exhibits Break Bayview Foyer A
10:00 am - 11:00 am	Scientific Session 8: Advanced Imaging & Artificial Intelligence Bayview Room <i>Moderators: David Lim, MD, PhD & Nikoo McGoldrick</i> • Clinical trial on AI detection of ILC on mammography — Manisha Bahl, MD • Contrast enhanced mammography in ILC — Molly Hogan, MD • Whole body MRI for metastatic ILC — Elleke Dresen, MD, PhD
11:00 am - 11:30 am	Dynami Foundation Leigh Pate Memorial Lecture Bayview Room Historical Perspective: 10 years since first ILC Symposium LECTURER: Steffi Oesterreich, PhD
11:30 am - 12:00 pm	Presentation on advocacy in ILC Bayview Room <i>Rita Mukhtar, MD, 2026 ILC Symposium Host</i>
12:00 pm - 1:00 pm	Lunch Bayview Room
1:00 pm - 2:15 pm	Scientific Session 9: SNMMI Special Session — Imaging in ILC Bayview Room <i>Moderators: Mateus de Oliveira Taveira, MD & Amy Russell-Parliman</i> • ILC: Review of initial staging modalities, CT, and bone scan — Gary Ulaner, MD, PhD • Staging solutions for metastatic disease: FDG and FES PET — Hannah Linden, MD • Emerging PET imaging modalities: FAPI and PSMA — Wenhui Zhou, MD, PhD • Research and trials regarding theranostics for breast cancer — David Mankoff, MD, PhD
2:15 pm - 2:45 pm	Snacks and Exhibits Break Bayview Foyer A
2:45 pm - 3:45 pm	Scientific Session 10: Radiotherapy, Clinical Trials Bayview Room <i>Moderators: Meghan R. Flanagan, MD, MPH & Brenda Sulick, PhD</i> • Dysfunctional DNA repair: PARPi and radiation sensitivity in ILC — Matt Sikora, PhD • Tumor heterogeneity from autopsy studies — Christine Desmedt, PhD • Radiotherapy in ILC — Elinor Sawyer, PhD
3:45 pm - 4:15 pm	Debate 3: Patients with ILC should be treated with neoadjuvant therapy Bayview Room SPEAKERS: Jo Chien, MD and Julia Foldi, MD, PhD
4:15 pm - 4:30 pm	Closing the symposium Bayview Room

Sponsors

Thank you to our sponsors!
Your generosity advances ILC awareness and research.

Platinum Level



Gold Level



Bronze Level



Sponsor



Keynote Speakers



Parry Guilford, PhD, MSc

Professor Parry Guilford is a Principal Investigator in the Cancer Genetics Laboratory, University of Otago and co-founder of the cancer diagnostics company Pacific Edge Ltd. His current research interests include the genetics of inherited and sporadic cancers, in particular stomach and breast cancer. He led the research group that first described the inherited cancer syndrome Diffuse Gastric and Lobular Breast Cancer Syndrome, and he continues to work on approaches for the chemoprevention and treatment of these cancers.

Laura Esserman, MD, MBA

Laura Esserman, MD, MBA is the director of the UCSF Breast Care Center, and is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design. She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded WISDOM Study, which tests a personalized approach to breast cancer screening in 100,000 women. She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers.



Steffi Oesterreich, PhD

Steffi Oesterreich, PhD is Professor of Pharmacology and Chemical Biology and Director of Education, Women's Cancer Research Center at the University of Pittsburgh. The main interest of Dr. Oesterreich's research is to further our understanding of hormone action in women's cancer for improved diagnosis and endocrine treatment. Her studies have focused on breast cancer and receptor action in ovarian cancer. The Oesterreich lab is interested in novel concepts of ER action, such as its role in repression of gene transcription and its role in epigenetic marks in the genome. In her role as Director of Training in the Women's Cancer Research Center, she is interested in providing outstanding training opportunities to the next generation of women's cancer researchers.

Session Speakers

Debate #1

TOPIC: TUMOR MORPHOLOGY ALONE SHOULD BE USED TO DIAGNOSE ILC



Fouad Boulos, MD

Dr. Fouad Boulos is a breast pathologist who trained at Vanderbilt under mentors David Page and Jean Simpson. After 10 years at the American University of Beirut in Lebanon, he became the head of breast pathology at Washington University in St. Louis. Dr. Boulos is dedicated to education, research, and a deeper understanding of the more challenging and contentious aspects of breast pathology.

Stu Schnitt, MD

Stuart J. Schnitt, MD is the Chief of the Division of Cancer Pathology at Beth Israel Deaconess Medical Center, Chief of Oncologic Pathology at the Dana-Farber Cancer Institute, Professor of Pathology at Harvard Medical School, and is an internationally recognized expert in breast pathology. He has authored a popular breast pathology textbook entitled "Biopsy Interpretation of the Breast," now its fourth edition.



Anne Vincent-Salomon, MD, PhD

Anne Vincent-Salomon has led the Department of Pathology at the Institut Curie for 21 years. She has a MD degree from the University Paris VI and a PhD degree from Paris Sud University. Her domains of expertise are breast, surgical, and hematopathology. Her commitment for breast pathology motivates her work to reinforce breast tumor characterization using immunohistochemistry as well as molecular tools.

Session #1

GENETICS, RISK, AND EXPOSURES



Giovanni Corso, MD, PhD

Prof. Giovanni Corso MD, PhD is associate professor in general surgery at the University of Milan and breast surgeon at the European Institute of Oncology, Milan, Italy. Author of more than 200 papers published in international journals, and editor of three books. Principal investigator of five research-funded projects. Invited speaker at 40 national and international cancer congresses.

Cathrin Briskin, MD, PhD

Cathrin Briskin obtained her MD and a PhD in Biophysics from the University of Göttingen, Germany. She established her research line at the Whitehead Institute, and held appointments at the Cancer Center of the Massachusetts General Hospital, Harvard Medical School and the Swiss Institute for Experimental Cancer Research. Her research focuses on endocrine control mechanisms of breast cancer development.



Mindy Goldman, MD

Dr. Mindy Goldman is a Clinical Professor in the Department of Obstetrics and Gynecology and Director of the Women's Cancer Care Program at UCSF. Her clinical expertise focuses on the gynecologic issues for women who have had or are at high risk for breast cancer. She has become a nationally recognized expert and helped author the American College of Gynecology (ACOG) Technical Bulletin.

Tari King, MD

Dr. Tari A. King is the Nancy Stonecipher Professor in Cancer Innovation and Chief Surgical Officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. She also serves as chief of the Division of Breast Surgery in the Department of Surgery at Emory University and as Surgical Director of the Winship Glenn Family Breast Center.



Session Speakers

Session #2

THE ILC CELL & MICROENVIRONMENT



Chip Petricoin, PhD

Dr. Emanuel F Petricoin is the Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University. He is a PI on numerous precision oncology trials including the I-SPY2 TRIAL, and a co-founder of 3 life science companies. His expertise includes precision oncology and medicine, development of genomics and proteomics-based companion diagnostics, and protein biomarkers.

Fatima Mechta-Grigoriou, PhD

F. Mechta-Grigoriou is an internationally recognized expert investigating the impact of tumor heterogeneity in immunosuppression, metastatic spread and resistance to treatment. Her lab has identified different cancer-associated fibroblast (CAF) populations in several cancer types, revealing that some specific CAF populations are involved in immunosuppression and resistance to immunotherapies.



Rebecca Riggins, PhD

Rebecca Riggins, PhD, Professor of Oncology at Georgetown University and the Lombardi Comprehensive Cancer Center (LCCC), is a basic and translational scientist. Her laboratory studies the role of nuclear receptors in breast and brain cancers, and is currently supported by the National Cancer Institute, the American Cancer Society, and the Breast Cancer Research Foundation.

Wayne Stallaert, PhD

Dr. Wayne Stallaert is an Assistant Professor in the Department of Computational and Systems Biology and Principal Investigator at the UPMC Hillman Cancer Center at University of Pittsburgh. Combining live-cell and highly multiplexed single-cell imaging with computational approaches, his research focuses on how cancer cells adapt their proliferative programs to changing environmental or internal conditions.



Session #3

MECHANISMS OF METASTASIS



Kevin Cheung, MD

Dr. Kevin Cheung, MD is an Associate Professor and medical oncologist at the Fred Hutchinson Cancer Center. Dr. Cheung's research is focused on understanding the molecular and cellular factors that control breast cancer metastasis and the role of multicellular collective interactions in this process. His laboratory combines clinical studies in human tumor samples with experimental studies using new technologies.

Jay Debnath, MD

Jayanta Debnath is Distinguished Professor and Chair of Pathology at University of California, San Francisco, and a member of the Helen Diller Family Comprehensive Cancer Center, Bakar Immuno-X Program and Bakar Aging Research Institute. His lab focuses on how autophagy influences breast cancer metastasis and recurrent disease, and targeting the core autophagy machinery for therapeutic benefit.



Chris Lord, PhD

Prof. Chris Lord is Deputy Head of Division, Team Leader of the CRUK Gene Function Lab and Prof. of Cancer Genomics in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London. His work focuses on exploiting genetic concepts such as synthetic lethality to identify new approaches to treating cancer and to understand the variable effectiveness of existing treatments.

Valerie Weaver, PhD

Dr. Weaver is Director of the Center for Bioengineering and Tissue Regeneration in the Surgery Department, with a cross-appointment in Bioengineering and Therapeutic Sciences at UCSF. After her training, she joined the Pathology Department at the University of Pennsylvania and IME, after which she joined the Surgery Department at UCSF.



Session Speakers

Debate #2

TOPIC: CYTOTOXIC CHEMOTHERAPY IS INEFFECTIVE IN PATIENTS WITH METASTATIC ILC



Rebecca Shatsky, MD

Dr. Rebecca Shatsky serves as the director of breast medical oncology at the University of California, San Diego Moores Cancer Center. Dr. Shatsky's clinical and translational research focuses on the treatment of metastatic/stage IV lobular breast cancer, triple-negative breast cancer, and breast cancer with brain metastases and/or leptomeningeal disease.

Sherry Shen, MD

Dr. Sherry Shen is a medical oncologist and clinical investigator on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as co-director of the MSK Lobular Breast Cancer Program, one of the first dedicated clinical programs in the country for patients with ILC. Her research centers on optimizing treatment efficacy and tolerability for patients with HR-positive breast cancer.



Session #4

MODEL SYSTEMS & PATHOLOGY



Adrian Lee, PhD

Dr. Adrian Lee is Professor of Pharmacology & Chemical Biology at the University of Pittsburgh and UPMC Hillman Cancer Center. He is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM). The laboratory studies the molecular basis of breast cancer development and resistance to therapy, with the goal to improve precision medicine and outcomes.

Yi Li, PhD

Dr. Yi Li is a Professor in the Breast Center, Baylor College of Medicine in Houston. He earned his PhD at Michigan State University. He then trained with Dr. Harold Varmus at NCI and then at MSKCC. In 2002, Dr. Li was recruited to Baylor to start his independent faculty position. His lab investigates the molecular and cellular mechanisms of breast cancer initiation and progression as well as prevention and treatment.



Lounes Djerroudi, MD, PhD

Lounes Djerroudi, MD, PhD is a Pathologist and researcher at Institut Curie, currently serving as a Visiting Investigator at Memorial Sloan Kettering Cancer Center. His work integrates diagnostic pathology with molecular biology, with a primary focus on lobular breast cancer. His work aims to improve breast cancer classification and prognostic prediction through high-resolution technologies and artificial intelligence.

Ruth Keri, PhD

Dr. Ruth Keri is the Associate Director for Basic Research in the Case Comprehensive Cancer Center. She earned her doctorate and completed her postdoctoral studies at CWRU. Her research program specializes in identifying transcriptional and signaling mechanisms that control breast development, cancer initiation, and progression to discover new therapeutic approaches for treating aggressive disease.



Session Speakers

Session #5

DIAGNOSTICS & CLINICAL MANAGEMENT



Rachel Jankowitz, MD

Dr. Jankowitz is an Associate Professor of Clinical Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania, and Director of the Rena Rowan Breast Center at the Penn Abramson Cancer Center. Her research focuses on invasive lobular breast cancer, with a particular interest in biomarker development and treatment response in patients with ILC.

Karen van Baelen, MD, PhD

Karen Van Baelen, MD, PhD is a postdoctoral research fellow at the Laboratory for Translational Breast Cancer Research at KU Leuven, under the supervision of Prof. Christine Desmedt. Originally trained in Gynecology and Obstetrics, she developed a strong interest in breast cancer research, with a particular focus on invasive lobular carcinoma (ILC).



Priscilla McAuliffe, MD, PhD

Priscilla McAuliffe, MD PhD, is a breast surgical oncologist at UPMC Hillman Cancer Center, and an assistant professor of surgery at the University of Pittsburgh School of Medicine. Her research focuses on invasive lobular breast cancer, pre-invasive neoplasms such as DCIS and LCIS, premenopausal and elderly breast cancer, breast conservation therapy and locally advanced breast cancer.

Jason Mouabbi, MD

Jason A. Mouabbi, MD is an Assistant Professor of Oncology in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. His research focuses on investigating the unique biology of invasive lobular carcinoma compared to invasive ductal carcinoma and developing and evaluating cutting-edge therapies for metastatic hormone receptor-positive (HR+) breast cancer.



Session #6

CLINICAL TRIAL RESULTS & ADVOCACY



Rinath Jeselsohn, MD, PhD

Dr. Jeselsohn is a breast medical oncologist and physician scientist and leads a breast cancer translational research lab affiliated with the Molecular and Cellular Oncology Division at Dana-Farber. Her work has led to the identification and characterization of estrogen receptor mutations as the most common genetic mechanism of acquired endocrine resistance in metastatic hormone receptor positive breast cancer.

Laura Kennedy, MD, PhD

Laura Kennedy, MD, PhD is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt University Medical Center. Her research focuses on developing biomarkers and targeted therapeutics to improve outcomes for patients with a special focus on triple-negative and lobular breast cancers.



Maria Karsten, MD

Prof. Maria Karsten is a lead senior physician at the Charité Breast Center in Berlin, Germany. She is a Society of Surgical Oncology-trained breast surgeon and is board-certified in obstetrics and gynecology. Prof. Karsten's clinical and research work focuses on improving outcomes and quality of life for patients with breast cancer, with particular emphasis on patient-reported outcomes (PROs).

Mo Rimawi, MD

Dr. Rimawi is the Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. His research focuses on translational clinical trials, drug development, and biomarker discovery. His work helped develop dual HER2 inhibition, concurrent targeting of ER and HER2, and treatment de-escalation in HER2-positive breast cancer.



Session Speakers

Session #7

ENDOCRINE RESISTANCE & NOVEL TARGETS



Ariella Hanker, PhD

Dr. Ariella Hanker is an associate professor in the Simmons Comprehensive Cancer Center at UTSouthwestern Medical Center in Dallas, TX. Her translational breast cancer research focuses on defining and therapeutically targeting genomic alterations and oncogenic signaling pathways that drive breast cancer growth and drug resistance.

François Richard, PhD

François Richard, PhD, is a Research Expert in Bioinformatics at the Laboratory for Translational Breast Cancer Research (KU Leuven). His work bridges computational biology, tumour evolution, and clinical biomarker development. He is involved in international research efforts, including the European Lobular Breast Cancer Consortium, contributing bioinformatic expertise to better define ILC and its subtypes.



Patrick Derksen, PhD

Patrick Derksen, PhD, is a Professor of Experimental and Preclinical Oncology at UMC Utrecht. His group aims to combine expertise on adhesion molecules, cell signaling and clinically relevant mouse models to study the downstream effectors of the adherens junction complex that propel breast cancer development and progression.

Session #8

ADVANCED IMAGING & ARTIFICIAL INTELLIGENCE



Manisha Bahl, MD

Manisha Bahl, MD, MPH, FSBI, is a breast imaging radiologist at Massachusetts General Hospital, Associate Medical Director of Quality for Breast Imaging at Mass General Brigham, and Associate Professor of Radiology at Harvard Medical School. Her research focuses on AI and advanced breast imaging technologies to improve breast cancer detection, with a particular interest in ILC.

Molly Hogan, MD

Molly Hogan is an Assistant Attending in Radiology at Memorial Sloan Kettering Cancer Center. Her research interests include the accurate diagnosis and treatment of breast cancers with non-traditional presentations, including ILC, as well as expanding options available for screening women of intermediate to high risk of developing breast cancer with an emphasis on contrast enhanced mammography.



Elleke Dresen, MD, PhD

Elleke Dresen is an abdominal and oncological radiologist at the University Hospitals Leuven in Belgium, mainly focusing on pelvic MRI and whole-body diffusion-weighted MRI in patients with gastro-intestinal, colorectal and gynaecological cancer. Her dissertation was addressed to the multidisciplinary approach to rectal cancer. She is partly employed as an assistant professor at KU Leuven.

Session Speakers

Session #9

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPECIAL SESSION — IMAGING IN ILC



Gary Ulaner, MD, PhD

Dr. Gary Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at the Hoag Family Cancer Institute and Professor of Radiology and Cancer Biology at the University of Southern California. Gary has been the principal investigator of prospective clinical trials for 20+ novel PET radiotracers and radiopharmaceutical therapy agents for patients with breast cancer and other cancers.

Hannah Linden, MD

Dr. Hannah Linden is associate program director of the Medical Oncology and Hematology Fellowship Program at Fred Hutch and UW Medicine. Dr. Linden studies new breast cancer therapies and molecular imaging techniques, such as using PET scans to confirm the effectiveness of estrogen-blocking and estrogen-depleting therapy in patients with metastatic breast cancer.



Wenhui Zhou, MD, PhD

Wenhui Zhou, MD, PhD is a radiologist specializing in breast and PET imaging at the University of Wisconsin School of Medicine and Public Health. As a physician-scientist, Dr. Zhou's research focuses on precision cancer imaging with two complementary approaches: 1) integrating multimodal imaging and non-imaging data, and 2) validating new biologically targeted radiopharmaceuticals.

David Mankoff, MD, PhD

Dr. David Mankoff is the Matthew J. Wilson Professor and Vice-Chair for Research in the Radiology Department of the Perelman School of Medicine at the University of Pennsylvania. Dr. Mankoff's research focuses on molecular imaging of cancer and emphasizes molecular imaging biomarkers for precision oncology, therapeutic monitoring, and biologic factors mediating therapeutic response and resistance.



Session #10

RADIOTHERAPY, CLINICAL TRIALS



Matthew Sikora, PhD

Dr. Matthew Sikora is an Associate Professor of breast cancer research at the University of Colorado Anschutz Medical Campus. Research in the Sikora Lab is focused on understanding the function of the hormone estrogen and anti-estrogen therapies in breast cancer, with a special focus on invasive lobular carcinoma (ILC).

Christine Desmedt, PhD

Christine Desmedt, PhD is an Associate Professor at the Katholieke Universiteit Leuven, where she leads the Laboratory for Translational Breast Cancer Research. Her research focuses on the molecular characterization of breast cancer, better understanding rarer cancer subtypes, identification of mechanisms of treatment efficacy, and exploring the impact of patient adiposity on breast cancer biology.



Elinor Sawyer, PhD

Dr. Elinor Sawyer is a Clinical Oncologist. Her research interests are genetic predisposition to breast cancer particularly lobular breast cancer and DCIS, and identification of biomarkers that predict progression of LCIS and DCIS. Dr. Sawyer studied medicine at UCL and trained in oncology at Middlesex, Royal Free and St Thomas' Hospitals. Her PhD is in Molecular and Population Genetics at the London Research Institute.

Session Speakers

Debate #3

TOPIC: PATIENTS WITH ILC SHOULD BE TREATED WITH NEOADJUVANT THERAPY



Jo Chien, MD

Dr. Chien is a Professor of Medicine and the Medical Director for Breast Medical Oncology at UCSF. Her research focuses on the translational and clinical development of novel treatment strategies for early stage and metastatic breast cancer. Dr. Chien aims to identify which patients need more aggressive treatment and which patients can do well with less intervention.

Julia Foldi, MD, PhD

Dr. Foldi is an Assistant Professor of Medicine in the Division of Hematology/Medical Oncology at the University of Pittsburgh School of Medicine and a clinician-scientist at UPMC Hillman Cancer Center and Magee-Womens Hospital. She is a Clinical and Translational Science Scholar at the University of Pittsburgh. Her research focuses on ILC, with emphasis on circulating tumor DNA and CDK4/6 inhibitor biology.



Conference Abstracts

Poster Session: Wednesday, September 23

5:30 PM - 7:30 PM, Garden Room

PRESENTING AUTHOR	CATEGORY	POSTER TITLE	LOCATION
Alyssa Pama	Clinical Research	Histologic subtype of nodal metastases in patients with invasive mixed ductal and lobular tumors: a preliminary analysis	6E
Andrea M Dickey	Translational Research	Invasive Lobular Carcinoma with Solid Papillary Pattern (ILC-SP) – A Multi-institutional Study with Clinicopathologic and Molecular Characterization	4B
Anna Beck	Translational Research	Differential somatic mutation status in pN2-3 invasive lobular cancer and associated clinical outcomes	5B
Anna Vertido	Clinical Research	Impact of neoadjuvant therapy type on positive margin rates in patients with invasive lobular carcinoma in the National Cancer Database	5D
Annapurna Gupta	Translational Research	Arginine Deprivation and Arginine-targeted Therapy Suppress Tumor Growth in Tamoxifen-Resistant Invasive Lobular Carcinoma via Impaired Mitochondrial Function	5C
Astrid Quirarte	Clinical Research	Evaluation of the use of Neoadjuvant CDK4/6 Inhibitors with Endocrine Therapy for Patients with Invasive Lobular Carcinoma	5F
Brooke Vittimberga	Clinical Research	Invasive Lobular Carcinoma and Menopausal Status: Surgical Outcomes and Recurrence-Free Survival in Premenopausal Patients	5E
Chinasa Ufodu	Basic Science Research	E-cadherin loss reprograms cellular metabolism and drives tumorigenesis in human mammary epithelial cells.	5I
Claire Turner	Other	"Not a chance [of MRI]... It's not going to happen": the psychological burden of post-treatment surveillance among UK women with invasive lobular carcinoma	1G
Deviyani Rao	Basic Science Research	Dissecting the role of MDC1 in ER-driven transcriptional programs in ILC cells via single-cell transcriptomics	5H
Elisabeth Abeles	Clinical Trial	A Novel PET Imaging Tracer for Invasive Lobular Carcinoma: Fibroblast Activation Protein	6D
Esme Bullock	Basic Science Research	RHOA mutations alter the RhoA interactome and metastatic tropism in Invasive Lobular Carcinoma.	4G
Nicholas C. Turner (Genentech)	Other	Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).	3G
Peter Schmid (Genentech)	Other	Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2- eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.	3H
Grazia Castellano	Review	CDK4/6 inhibitors (CDK4/6i) in metastatic invasive lobular breast cancer (mILC): a systematic review of histology-specific outcomes.	1H

Conference Abstracts

PRESENTING AUTHOR	CATEGORY	POSTER TITLE	LOCATION
Gregory Bean and Lixia Bai	Translational Research	Invasive lobular carcinoma with histiocytoid features: similarities and differences with apocrine carcinoma	3A
Gretel Silyn Roberts	Observational/ Real-world evidence studies	The Emerging Role of 68GA-FAPI PET/CT in Staging and Monitoring of Metastatic Invasive Lobular Breast Cancer Treated with Trastuzumab Deruxtecan: A Case Report	3I
Insa Thale	Basic Science Research	Defining How CDH1 Loss Shapes Immune Composition and Macrophage Polarization in a Syngeneic ER+ ILC-like Model	4F
Jackelyn Moya	Clinical Research	Clinicopathologic Characteristics and Treatment by Menopausal Status in Patients with Invasive Lobular Carcinoma: A Single-Institution Cohort Study	6A
Jackelyn Moya	Clinical Research	Clinicopathologic and Treatment Differences in Hereditary versus Sporadic Invasive Lobular Carcinoma of the Breast	6B
Jackelyn Moya	Clinical Research	Identifying Treatment Differences in Patients with Genomic Assay Scores within an Invasive Lobular Cancer Database	6C
Jasmine Phun	Clinical Research	Predicting Therapeutic Response to Neoadjuvant Chemotherapy in Invasive Lobular Cancer Subtypes	3F
Jordan Petrick	Translational Research	Upregulation of the Adaptive Immune Response and Risk of Future Breast Cancer in Patients with Lobular Carcinoma In Situ (LCIS)	1D
Jorine Sanders	Translational Research	Concomitant CDK4/6 and AKT inhibition as a synergistic targeted therapy for E-cadherin negative breast cancer	1B
Joseph L. Sottnik	Basic Science Research	Understanding the unique behavior of metastatic lobular breast cancer using advanced xenograft models	4I
Julia Houthuijzen	Basic Science Research	In vivo targeting of tumor cell-Cancer Associated Fibroblast crosstalk reveals critical mediators in invasive lobular breast cancer development	5G
Julie Ostrander	Basic Science Research	CDH1 loss remodels gene expression and lineage identity in human mammary epithelial cells	4J
Karen Van Baelen	Clinical Research	Oligometastatic disease at diagnosis in invasive lobular carcinoma: a single-center experience	4D
Karen Van Baelen	Clinical Trial	The DELILA trial: Disease Extent in stage IV Lobular carcinoma, the aid of Imaging and Liquid biopsy Analyses	4E
Katherine Russo	Clinical Research	Pre-Operative MRI and Surgical Outcomes in Invasive Lobular Carcinoma	1E
Lauren Grove	Translational Research	Zongertinib, a HER2 Tyrosine Kinase Inhibitor, Demonstrates Efficacy in Models of ERBB2-Mutant Invasive Lobular Carcinoma as Monotherapy and in Combination with T-DXd	3B
Lavinia Middleton	Clinical Research	The Effect of Germline Pathogenic Variants in the Upgrade Rate to Breast Cancer among Patients Diagnosed with Atypical Lobular Hyperplasia and Lobular Carcinoma in Situ on Core Needle Biopsy	3E
Mackenzey Mull	Other	Potential for Androgen Receptors as a Therapeutic Target for Invasive Lobular Breast Cancer	2F
Maria Gabriela Raso	Observational/ Real-world evidence studies	Clinicopathologic Features of Triple Negative Invasive Lobular Carcinoma: A Single Institution Cohort with Paired Biopsy and Surgical Histology Review	3J

Conference Abstracts

PRESENTING AUTHOR	CATEGORY	POSTER TITLE	LOCATION
Mark Magbanua	Translational Research	Prognostic significance of circulating tumor DNA in early-stage high-risk invasive lobular breast cancer	2C
Martha Gutteridge	Basic Science Research	STAT3 signalling is activated in CDK4/6 inhibitor-resistant metastatic lobular breast cancer, and is inhibited by SFX-01, reducing patient-derived tumour growth and stem cell activity	4H
Mary Elizabeth Buchanan	Clinical Research	ILC bone metastases present inter- and intra-lesion heterogeneity for sclerotic versus lytic remodeling	3D
Matthew Sikora	Other	Structural and socioeconomic factors may drive disparities in lobular breast cancer diagnosis	2G
Milana Bergamino Sirvén	Clinical Research	Distinct Early Molecular Remodelling and Histology-Specific Adaptive Responses in ER+/HER2- Invasive Lobular Carcinoma: A Pooled Analysis of SOLT1 Preoperative Trials	1F
Minakshi Gandhi	Translational Research	Establishment and Characterization of a Patient-Derived Organoid Biobank for Functional Precision Oncology in Invasive Lobular Carcinoma	4C
Minhal Zaidi	Review	Retrospective review of Clinicopathologic features in HER2-positive Invasive Lobular Carcinoma	2H
Raza Hoda	Translational Research	Triple-Positive Invasive Lobular Carcinoma: Clinicopathologic Features, Therapeutic Response to Neoadjuvant Chemotherapy, and Long-Term Outcomes	1C
Rodoniki Iosifidou	Observational/ Real-world evidence studies	Recurrence Score Distribution and Clinical Implications of Oncotype DX in Invasive Lobular Breast Cancer: A Single-Center Real-World Cohort	2I
Sasha Stanton	Translational Research	Immune environment of invasive lobular breast cancer is more immunosuppressive than lobular carcinoma in situ regardless of breast cancer subtype.	3C
Shefali Thakur	Translational Research	Targeting Metastatic Invasive Lobular Carcinoma.	4A
Thurkaa Shanmugalingam	Translational Research	Longitudinal Tracking of Tumour Burden in Metastatic Lobular Breast Cancer	1A
Traci Lyons	Translational Research	SEMA7A promotes invasion of lobular breast cancers and is a novel therapeutic target	2A
Venezia Garza	Clinical Research	Analysis of pre-treatment MRI and post-neoadjuvant therapy pathology in patients with invasive lobular carcinoma	6F
Wenhui Zhou	Clinical Research	Clinical Utility and Management Impact of 18F-FES PET/CT for Lobular Breast Cancer	2D
Wenhui Zhou	Clinical Research	Occult Axillary Nodal Metastasis on Standard-of Care Imaging in Invasive Lobular Breast Cancer	2E
William Yang	Translational Research	CDH1 mutation creates a centrosomal Aurora A deficiency that confers synthetic lethality in invasive lobular breast cancer.	2B
Ziqi Wang	Translational Research	Pilot Transcriptomic Analysis of TBCRC037, A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer (NCT02206984)	5A

Awards for Abstract Submissions

Komen Early Career Investigator Award Recipients



Anna Vertido, MD




Brent Schlegel, BS



Camille Carette, MS



Christopher Merkel, BS




Darcie Seachrist, PhD



Eduardo Peña, PhD




Elisabeth Abeles, MD



Julia Ye, MD, PhD




Marni McClure, MD, PhD



Sumayya Abdul Qadir, BS

Sponsored by the Susan G. Komen Foundation

ILC Travel Grant Award Recipients



Amy McCart Reed, PhD



Chamil Jinadasa, MD



Esme Bullock, PhD



Insa Thale, PhD



Jorine Sanders, MS




Karen Van Baelen, MD, PhD



Melanie Salvador, BS



Milana Bergamino Sirvén, MD, PhD




William Yang, PhD

Sponsored by the Breast Cancer Research Foundation and California Breast Cancer Research Program

2026 ILC Symposium Overall Best Abstract Awardees



Jason Mouabbi, MD



Sumayya Abdul Qadir, BS

Scientific Planning Committee



Anne Vincent-Salomon, MD, PhD

Department Head of Pathology and Pole Coordinator of Pathology-Genomics and Immunology, Institut Curie



Christine Desmedt, PhD

Assistant Professor of Oncology, KU Leuven, Head of the Laboratory for Translational Breast Cancer Research



Matthew Sikora, PhD

Associate Professor, Department of Pathology, University of Colorado, Anschutz Medical Campus



Patrick Derksen, PhD

Professor of Experimental and Preclinical Oncology, University Medical Center Utrecht



Peter Simpson, PhD

Professor, Centre for Clinical Research, University of Queensland, Australia



Rachel C. Jankowitz, MD

Associate Professor of Clinical Medicine, University of Pennsylvania, Director of the Rena Rowan Breast Center at Abramson Cancer Center



Rita Mukhtar, MD

Professor of Surgery, University of California San Francisco, Program Director of the UCSF Lobular Breast Cancer Research Program



Steffi Oesterreich, PhD

Professor, University of Pittsburgh, Co-Director, Women's Cancer Research Center, Co-Leader Cancer Biology Program, UPMC HCC and MWRI

Advocate Planning Committee



Deborah Romer, MBA
Advocate Planning
Committee Co-Chair,
Advocate for Lobular Breast
Cancer Alliance and National
Breast Cancer Coalition
Board Member, Breast
Cancer Care and Research
Fund



Laurie Hutcheson, MS
Advocate Planning
Committee Co-Chair,
Patient Advocate &
Executive Director
Lobular Breast Cancer
Alliance Inc.



Barbara Neilsen
Patient Advocate for
Lobular Breast Cancer
Alliance



Claire Turner
Interim CEO Lobular
Breast Cancer UK and
European Lobular Breast
Cancer Advocate



Lori Petitti
Advocate for Lobular
Breast Cancer Alliance
and National Breast
Cancer Coalition,
President, Breast Cancer
Care and Research Fund



Tone Lien
Patient Advocate
European Lobular Breast
Cancer Consortium,
from Oslo, Norway

Local Planning Committee



Alli Veronello, BA
Business Operations
Analyst, UCSF Breast
Care Center



Anjali Vaidya, MPH
Program Coordinator,
UCSF Lobular Breast
Cancer Research
Program



Astrid Quirarte, BA
Program Coordinator,
UCSF Lobular Breast
Cancer Research
Program



Cindy Li, BA
Business Operations
Supervisor, UCSF Breast
Care Center



Francesca de las Alas, BA
Manager of Curriculum
Services, UCSF Breast
Care Center



Flora Migyanka
Founding Patient
Advocate, LBCA; Founder,
The Dynami Foundation



Jasmine Wong, MD
Associate Professor of
Surgery, University of
California, San Francisco



Sarah Feeley
Advocate, UCSF Lobular
Breast Cancer Research
Program



Rita Mukhtar, MD
Professor of Surgery,
University of California
San Francisco, Program
Director of the UCSF
Lobular Breast Cancer
Research Program



Venezia Garza, BA
Program Coordinator,
UCSF Lobular Breast
Cancer Research
Program

Explore San Francisco

During your time in San Francisco, discover what makes this city special! From waterfront walks and iconic landmarks to distinctive neighborhoods, museums, food, and views.

San Francisco's most iconic landmark, the **Golden Gate Bridge**, offers spectacular views of the city and bay. Walk part of its 1.7-mile span or explore the surrounding Presidio for some of the city's best viewpoints.

Distance from Hyatt Embarcadero: 6 miles



The historic **Ferry Building** offers beautiful architecture, a lively food marketplace, and sweeping San Francisco Bay views. The Ferry Plaza Farmer's Market is held Tuesdays, Thursdays, and Saturdays.

Distance from Hyatt Embarcadero: 0.3 miles

Fisherman's Wharf is a lively waterfront district known for historic piers, seafood, shops, and the famous California sea lions at Pier 39. Take the historic F Market & Wharves streetcars for a unique SF experience.

Distance from Hyatt Embarcadero: 1.5 miles



Visit www.ilcsymposium.com/explore-san-francisco for more details about must-see landmarks, excursions, and more!

2028 Symposium Location

NEXT INTERNATIONAL
ILC SYMPOSIUM

Paris, France 2028

WE LOOK FORWARD TO
SEEING YOU THERE!





Sponsorship Highlights



ShareForCures™ | *susan g. komen.*

Help discover cures to breast cancer, **faster.**

ShareForCures™ is a breast cancer research registry by Susan G. Komen®, connecting researchers with information from people who have or had breast cancer.

Learn more at **shareforcures.org**.



GE HealthCare

CERI⁺ANNA™
(FLUOROESTRADIOL F 18) INJECTION

Sponsorship Highlights



IBCA[®] | Lobular Breast Cancer Alliance

The #1 source for information on lobular breast cancer

Join Us to **TALK ABOUT LOBULAR BREAST CANCER**

September 26th – October 15th!

Join us as we travel to 10+ cities across the US, stopping at 5 hospital ILC programs, events, and advocate gatherings to raise awareness of lobular breast cancer.

**LEARN
MORE**



**TIME 2 TALK
LOBULAR
BREAST
CANCER**

www.lobularbreastcancer.org

In Memoriam



Julia Katherine Levine

Julia Katherine Levine was a visionary advocate, co-founder of the Lobular Breast Cancer Alliance, and a true spitfire who inspired so many in the ILC community. She faced more than twelve years of metastatic ILC with remarkable courage, determination, humor, and generosity, while tirelessly advancing research and supporting others. Her strength, warmth, and unwavering commitment to improving the lives of people with ILC leave an extraordinary legacy.

Nancy Eisengruber MacGillivray

Nancy MacGillivray was a dedicated LBCA patient advocate and one of the sweetest, kindest people in the ILC community. She lived with metastatic breast cancer for many years with remarkable strength, warmth, and determination to live her best life, while generously supporting and encouraging others. Her kindness, joyful spirit, and dedication to LBCA and the ILC community touched so many and will be deeply missed.



Christine McKay

Christine McKay was a fierce and passionate advocate for lobular breast cancer and a founding member of the LBCA Patient Advocate Advisory Board. She worked tirelessly to amplify the patient voice, advance ILC research, and create a community where people could find information, support, and one another. Christine was truly a force, and her courage, compassion, and fierce determination will continue to inspire the ILC community.

In Memoriam



Karen Madaras

My mom Karen battled metastatic ILC for 4 years. During her fight she competed on American Ninja Warrior to raise awareness for ILC and inspire others living with metastatic breast cancer. She was my best friend and #1 supporter of my research, and she will be forever missed.

Mary Petitti

Mother, wife, sister, friend.



María Campuzano

María Campuzano was a light wherever she went: she championed the right to dignified water and energy access for those who have the least, and she faced her metastatic lobular breast cancer with the same confidence and the same smile she faced everything with. She was my patient, and I loved her dearly. Today we remember her with all our affection.

Notes

[illegible]

This image shows a full page of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page, typical of notebook paper. There are no margins, text, or other markings on the page.



ILC SYMPOSIUM 2026

2026 International Invasive Lobular Carcinoma Symposium



ILC Symposium
Website



UCSF Lobular Breast
Cancer Research
Program Website

2026 International Invasive Lobular Carcinoma Symposium

E: ilcresearch@ucsf.edu | W: www.ilcsymposium.com

Hosted by



Lobular Breast Cancer
Research Program
Department of Surgery

Organized by

